🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "major milestone" in the fight against increasingly resistant strains of the infection, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are on the rise worldwide, with figures suggesting over 82 million new cases each year. Particularly high rates are observed in the African continent and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely advancement in the reality of growing infection rates, escalating drug resistance and the highly restricted therapeutic options presently on offer.”

Health officials are particularly alarmed about the surge in drug-resistant strains. The WHO has classified it as a "high-priority threat". A tracking program found that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Receive Clearance

One new antibiotic, also known as Nuzolvence, was approved by the US Food and Drug Administration in recent days for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers believe that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, gained clearance in close succession. This drug, which is employed against UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This authorization represents a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Clinical Trial Outcomes and Global Access

Based on data detailed in a prominent scientific publication, zoliflodacin eradicated the vast majority of cases of the STI. This establishes an comparable level with the existing first-line therapy, which involves a dual-drug approach. The trial included nearly 1,000 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the rights to register and commercialise the drug in a wide range of developing nations.

Medical professionals directly involved have shared optimism. The availability of a easy-to-administer therapy of this kind is described as a "revolutionary step" for gonorrhoea control. This is deemed essential to lessen the impact of the infection for patients and to stop the proliferation of untreatable gonorrhoea globally.